ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)

ClinicalTrials.gov ID: NCT03150589

Public ClinicalTrials.gov record NCT03150589. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 7:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III Randomised, Double-masked, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity Between SB11 and Lucentis® in Subjects With Neovascular Age-related Macular Degeneration

Study identification

NCT ID
NCT03150589
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Samsung Bioepis Co., Ltd.
Industry
Enrollment
705 participants

Conditions and interventions

Interventions

  • Lucentis (ranibizumab) Drug
  • SB11 (Proposed ranibizumab biosimilar) Drug

Drug

Eligibility (public fields only)

Age range
50 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 13, 2018
Primary completion
May 23, 2019
Completion
Dec 8, 2019
Last update posted
May 20, 2021

2018 – 2019

United States locations

U.S. sites
19
U.S. states
12
U.S. cities
19
Facility City State ZIP Site status
Retina consultants San Diego Poway California 92064
Retina Consultants of Southern Colorado Colorado Springs Colorado 80909
Retina Consultants Fort Myers Florida 33912
Southeast Retina Center Augusta Georgia 30909
Retina Consultants of Hawaii ‘Aiea Hawaii 96701
Raj K. Maturi, MD, PC Indianapolis Indiana 46280
Retina Center of New Jersey, LLC Bloomfield New Jersey 07003
NJ Retina Toms River New Jersey 08755-8063
LIVR Great Neck New York 11021
Long Island Vitreoretinal Consultants Hauppauge New York 11788
Retina Associates of Western NY Rochester New York 14620
Retina Vitreous Surgeons fo Central NY, PC Syracuse New York 13224
Retina Associates of Cleveland Middleburg Heights Ohio 44130
Charleston Neuroscience Institute Ladson South Carolina 29414
Black Hills Regional Eye Institute Rapid City South Dakota 57701
Retina Research Institute of Texas Abilene Texas 79606
Austin Restina Associates Austin Texas 78705
Retina consultants of Houston Conroe Texas 77030
Retina Consultants of Houston Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 56 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03150589, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 20, 2021 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03150589 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →